[8-K] BURLINGTON STORES, INC. Reports Material Event
Aclaris Therapeutics (Nasdaq: ACRS) has filed a Form 8-K to inform investors that it will host a conference call on 29 Jul 2025 to review top-line data from its Phase 2a study of ATI-2138, an oral covalent ITK/JAK3 inhibitor for moderate-to-severe atopic dermatitis. Two items are furnished: Exhibit 99.1 (investor presentation) and Exhibit 99.2 (press release). Under Reg FD, Items 7.01 and 8.01 are furnished—not filed—so the information is not subject to Exchange Act liability nor automatically incorporated into other SEC reports.
The 8-K contains no numerical efficacy, safety, or financial metrics. Investors must consult the accompanying exhibits or join the conference call for detailed results. No changes to financial statements or previously issued guidance are included.
Aclaris Therapeutics (Nasdaq: ACRS) ha presentato un modulo 8-K per informare gli investitori che terrà una conference call il 29 luglio 2025 per esaminare i dati preliminari del suo studio di Fase 2a su ATI-2138, un inibitore orale covalente di ITK/JAK3 per la dermatite atopica da moderata a grave. Sono forniti due documenti: l'Esibizione 99.1 (presentazione per investitori) e l'Esibizione 99.2 (comunicato stampa). Ai sensi del Reg FD, gli elementi 7.01 e 8.01 sono forniti ma non depositati, quindi le informazioni non sono soggette a responsabilità secondo lo Exchange Act né automaticamente integrate in altri rapporti SEC.
Il modulo 8-K non contiene dati numerici sull'efficacia, la sicurezza o metriche finanziarie. Gli investitori devono consultare gli allegati o partecipare alla conference call per i risultati dettagliati. Non sono incluse modifiche ai bilanci o alle precedenti previsioni.
Aclaris Therapeutics (Nasdaq: ACRS) ha presentado un Formulario 8-K para informar a los inversores que realizará una llamada de conferencia el 29 de julio de 2025 para revisar los datos preliminares de su estudio de Fase 2a sobre ATI-2138, un inhibidor oral covalente de ITK/JAK3 para dermatitis atópica moderada a grave. Se proporcionan dos documentos: Exhibición 99.1 (presentación para inversores) y Exhibición 99.2 (comunicado de prensa). Según el Reg FD, los ítems 7.01 y 8.01 se proporcionan pero no se presentan oficialmente, por lo que la información no está sujeta a responsabilidad bajo la Ley de Intercambio ni se incorpora automáticamente en otros informes de la SEC.
El 8-K no contiene datos numéricos sobre eficacia, seguridad ni métricas financieras. Los inversores deben consultar los anexos o unirse a la llamada para obtener resultados detallados. No se incluyen cambios en los estados financieros ni en las previsiones anteriores.
Aclaris Therapeutics (나스닥: ACRS)는 2025년 7월 29일 구두 ITK/JAK3 억제제인 ATI-2138의 2a상 임상시험 주요 결과를 검토하기 위한 컨퍼런스 콜을 개최할 예정임을 투자자들에게 알리기 위해 Form 8-K를 제출했습니다. 두 가지 자료가 제공됩니다: 전시물 99.1(투자자 프레젠테이션)과 전시물 99.2(보도자료). Reg FD에 따라 항목 7.01과 8.01은 제출된 것이 아니라 제공된 것이므로, 이 정보는 거래법상 책임 대상이 아니며 다른 SEC 보고서에 자동 포함되지 않습니다.
8-K 문서에는 수치화된 효능, 안전성, 재무 지표가 포함되어 있지 않습니다. 투자자들은 상세 결과를 위해 첨부 자료를 참고하거나 컨퍼런스 콜에 참여해야 합니다. 재무제표 변경이나 이전 가이던스 변경 사항은 포함되어 있지 않습니다.
Aclaris Therapeutics (Nasdaq : ACRS) a déposé un formulaire 8-K pour informer les investisseurs qu'une conférence téléphonique se tiendra le 29 juillet 2025 afin de passer en revue les données préliminaires de son étude de phase 2a sur ATI-2138, un inhibiteur oral covalent d'ITK/JAK3 destiné à la dermatite atopique modérée à sévère. Deux documents sont fournis : Annexe 99.1 (présentation aux investisseurs) et Annexe 99.2 (communiqué de presse). Conformément au Reg FD, les points 7.01 et 8.01 sont fournis mais non déposés, ce qui signifie que les informations ne sont pas soumises à la responsabilité en vertu du Exchange Act ni automatiquement intégrées dans d'autres rapports SEC.
Le formulaire 8-K ne contient aucune donnée chiffrée concernant l'efficacité, la sécurité ou les indicateurs financiers. Les investisseurs doivent consulter les annexes ou participer à la conférence téléphonique pour obtenir des résultats détaillés. Aucun changement aux états financiers ni aux prévisions précédemment émises n'est inclus.
Aclaris Therapeutics (Nasdaq: ACRS) hat ein Formular 8-K eingereicht, um Investoren darüber zu informieren, dass am 29. Juli 2025 eine Telefonkonferenz stattfinden wird, um die Topline-Daten der Phase-2a-Studie zu ATI-2138, einem oralen kovalenten ITK/JAK3-Inhibitor für mittelschwere bis schwere atopische Dermatitis, zu besprechen. Zwei Anlagen werden bereitgestellt: Anlage 99.1 (Investorpräsentation) und Anlage 99.2 (Pressemitteilung). Gemäß Reg FD werden die Punkte 7.01 und 8.01 bereitgestellt, aber nicht eingereicht, sodass die Informationen keiner Haftung nach dem Exchange Act unterliegen und nicht automatisch in andere SEC-Berichte aufgenommen werden.
Das 8-K enthält keine numerischen Daten zu Wirksamkeit, Sicherheit oder Finanzkennzahlen. Investoren müssen die beigefügten Anlagen konsultieren oder an der Telefonkonferenz teilnehmen, um detaillierte Ergebnisse zu erhalten. Änderungen an den Finanzberichten oder zuvor veröffentlichten Prognosen sind nicht enthalten.
- Announcement of top-line Phase 2a results for ATI-2138 signals ongoing development progress and upcoming clinical visibility.
- Filing lacks any efficacy or safety data, leaving investors unable to gauge clinical success or valuation impact.
Insights
TL;DR: Filing announces forthcoming Phase 2a data; impact indeterminate until actual numbers released.
Pipeline progress matters in biotech valuations, and ATI-2138’s emergence from Phase 2a is a gating event. However, the 8-K omits efficacy or safety readouts, preventing assessment of clinical or commercial viability. Investors should withhold judgment until Exhibit 99.2 is reviewed or management comments on response rates, pruritus scores and adverse events.
TL;DR: Procedural 8-K; no immediate valuation catalyst without data.
The filing satisfies Reg FD by alerting the market to an upcoming disclosure. Because the information is furnished, it does not trigger SEC liability or automatic inclusion in future filings. Absent quantitative results, share-price impact is likely muted until the press release or call provides clarity on trial success, timeline to Phase 3 and funding needs.
Aclaris Therapeutics (Nasdaq: ACRS) ha presentato un modulo 8-K per informare gli investitori che terrà una conference call il 29 luglio 2025 per esaminare i dati preliminari del suo studio di Fase 2a su ATI-2138, un inibitore orale covalente di ITK/JAK3 per la dermatite atopica da moderata a grave. Sono forniti due documenti: l'Esibizione 99.1 (presentazione per investitori) e l'Esibizione 99.2 (comunicato stampa). Ai sensi del Reg FD, gli elementi 7.01 e 8.01 sono forniti ma non depositati, quindi le informazioni non sono soggette a responsabilità secondo lo Exchange Act né automaticamente integrate in altri rapporti SEC.
Il modulo 8-K non contiene dati numerici sull'efficacia, la sicurezza o metriche finanziarie. Gli investitori devono consultare gli allegati o partecipare alla conference call per i risultati dettagliati. Non sono incluse modifiche ai bilanci o alle precedenti previsioni.
Aclaris Therapeutics (Nasdaq: ACRS) ha presentado un Formulario 8-K para informar a los inversores que realizará una llamada de conferencia el 29 de julio de 2025 para revisar los datos preliminares de su estudio de Fase 2a sobre ATI-2138, un inhibidor oral covalente de ITK/JAK3 para dermatitis atópica moderada a grave. Se proporcionan dos documentos: Exhibición 99.1 (presentación para inversores) y Exhibición 99.2 (comunicado de prensa). Según el Reg FD, los ítems 7.01 y 8.01 se proporcionan pero no se presentan oficialmente, por lo que la información no está sujeta a responsabilidad bajo la Ley de Intercambio ni se incorpora automáticamente en otros informes de la SEC.
El 8-K no contiene datos numéricos sobre eficacia, seguridad ni métricas financieras. Los inversores deben consultar los anexos o unirse a la llamada para obtener resultados detallados. No se incluyen cambios en los estados financieros ni en las previsiones anteriores.
Aclaris Therapeutics (나스닥: ACRS)는 2025년 7월 29일 구두 ITK/JAK3 억제제인 ATI-2138의 2a상 임상시험 주요 결과를 검토하기 위한 컨퍼런스 콜을 개최할 예정임을 투자자들에게 알리기 위해 Form 8-K를 제출했습니다. 두 가지 자료가 제공됩니다: 전시물 99.1(투자자 프레젠테이션)과 전시물 99.2(보도자료). Reg FD에 따라 항목 7.01과 8.01은 제출된 것이 아니라 제공된 것이므로, 이 정보는 거래법상 책임 대상이 아니며 다른 SEC 보고서에 자동 포함되지 않습니다.
8-K 문서에는 수치화된 효능, 안전성, 재무 지표가 포함되어 있지 않습니다. 투자자들은 상세 결과를 위해 첨부 자료를 참고하거나 컨퍼런스 콜에 참여해야 합니다. 재무제표 변경이나 이전 가이던스 변경 사항은 포함되어 있지 않습니다.
Aclaris Therapeutics (Nasdaq : ACRS) a déposé un formulaire 8-K pour informer les investisseurs qu'une conférence téléphonique se tiendra le 29 juillet 2025 afin de passer en revue les données préliminaires de son étude de phase 2a sur ATI-2138, un inhibiteur oral covalent d'ITK/JAK3 destiné à la dermatite atopique modérée à sévère. Deux documents sont fournis : Annexe 99.1 (présentation aux investisseurs) et Annexe 99.2 (communiqué de presse). Conformément au Reg FD, les points 7.01 et 8.01 sont fournis mais non déposés, ce qui signifie que les informations ne sont pas soumises à la responsabilité en vertu du Exchange Act ni automatiquement intégrées dans d'autres rapports SEC.
Le formulaire 8-K ne contient aucune donnée chiffrée concernant l'efficacité, la sécurité ou les indicateurs financiers. Les investisseurs doivent consulter les annexes ou participer à la conférence téléphonique pour obtenir des résultats détaillés. Aucun changement aux états financiers ni aux prévisions précédemment émises n'est inclus.
Aclaris Therapeutics (Nasdaq: ACRS) hat ein Formular 8-K eingereicht, um Investoren darüber zu informieren, dass am 29. Juli 2025 eine Telefonkonferenz stattfinden wird, um die Topline-Daten der Phase-2a-Studie zu ATI-2138, einem oralen kovalenten ITK/JAK3-Inhibitor für mittelschwere bis schwere atopische Dermatitis, zu besprechen. Zwei Anlagen werden bereitgestellt: Anlage 99.1 (Investorpräsentation) und Anlage 99.2 (Pressemitteilung). Gemäß Reg FD werden die Punkte 7.01 und 8.01 bereitgestellt, aber nicht eingereicht, sodass die Informationen keiner Haftung nach dem Exchange Act unterliegen und nicht automatisch in andere SEC-Berichte aufgenommen werden.
Das 8-K enthält keine numerischen Daten zu Wirksamkeit, Sicherheit oder Finanzkennzahlen. Investoren müssen die beigefügten Anlagen konsultieren oder an der Telefonkonferenz teilnehmen, um detaillierte Ergebnisse zu erhalten. Änderungen an den Finanzberichten oder zuvor veröffentlichten Prognosen sind nicht enthalten.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant As Specified In Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices, including Zip Code)
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01. | Entry into a Material Definitive Agreement. |
On July 25, 2025, Burlington Coat Factory Warehouse Corporation (the “Company”), an indirect wholly-owned subsidiary of Burlington Stores, Inc., entered into a Sixth Amendment to Second Amended and Restated Credit Agreement (the “Amendment”), by and among the Company, as lead borrower, the other borrowers party thereto, the facility guarantors party thereto, the lenders party thereto and Bank of America, N.A., as administrative agent and collateral agent, which Amendment amends that certain Second Amended and Restated Credit Agreement dated as of September 2, 2011 (as previously amended, restated, supplemented, or otherwise modified prior to the date of the Amendment), by and among the Company, as lead borrower, the other borrowers party thereto, the facility guarantors party thereto, the lenders party thereto and Bank of America, N.A., as administrative agent and collateral agent. JPMorgan Chase Bank, N.A., Bank of America, N.A., and Wells Fargo Bank, National Association, acted as joint lead arrangers for the Amendment.
The parties entered into the Amendment in order to, among other things, (i) increase the aggregate principal amount of the commitments from $900 million to $1 billion and (ii) extend the maturity date of the commitments and loans from December 22, 2026 to July 25, 2030.
The foregoing description of the Amendment is qualified in its entirety by reference to such document, a copy of which is attached hereto as Exhibit 10.1 and is incorporated into this Item 1.01 by reference.
| Item 2.03. | Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. |
The information contained in Item 1.01 with respect to the Amendment is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. |
Description | |
| 10.1 | Sixth Amendment to Second Amended and Restated Credit Agreement, dated as of December 22, 2021, by and among Burlington Coat Factory Warehouse Corporation, as lead borrower, the other borrowers party thereto, the facility guarantors party thereto, each lender party thereto, and Bank of America, N.A., as administrative agent and collateral agent. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BURLINGTON STORES, INC. |
| /s/ David Glick |
| David Glick Group Senior Vice President of Investor Relations and Treasurer |
Date: July 29, 2025
FAQ
What did Aclaris Therapeutics (ACRS) announce in its 8-K?
Is the actual ATI-2138 Phase 2a data included in the filing?
What is ATI-2138?
Are the furnished materials considered "filed" with the SEC?
Will this 8-K affect Aclaris’s financial statements?
